09th week of 2016 patent applcation highlights part 9 |
Patent application number | Title | Published |
20160058724 | BACLOFEN FORMULATIONS AND METHODS FOR MAKING SAME - Methods for preparing sterilized baclofen solutions include adjusting the pH to below a desired pH, and steam sterilizing the solution with adjusted pH, which results in the solution having the desired pH. Such solutions may also have low concentrations of 4-CPP. Injectable baclofen solutions having greater than 2 mg/mL baclofen include between 5 mM and 25 mM of a phosphate or sulfate species. The solution has an ionic strength equivalent of about 1.5 M NaCl. The present application also provides baclofen formulations for use in treating spasticity, brain injury, cerebral palsy, spinal cord injury, cervical injury, multiple sclerosis, thoracic injury, or withdrawal symptoms. | 2016-03-03 |
20160058725 | Topical Formulations and Methods for Drug Delivery - Disclosed are topical formulations for delivery of an active ingredient to a patient. The formulation comprises components including: an active ingredient; a vasoactive agent; and a chelator, wherein the components are selected so that none of the other components is sequestered by the chelator. In some embodiments, the formulation comprises an osmolarity that is greater than about 345 milliOsmoles/liter (345 mOsM). In some embodiments, the formulation further comprises an osmolyte, wherein the osmoyte does not include an ion with a valency higher than monovalency. In some embodiments, the osmolyte in the formulation comprises an osmolarity that is greater than about 290 milliOsmoles/liter (290 mOsM). Also disclosed are methods for using the formulations, and components thereof, kits comprising the components of the formulation, and methods for manufacturing a medicament comprising components of the formulations. | 2016-03-03 |
20160058726 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN INJURY - Compositions and methods are provided for the alleviation of pathology induced by traumatic brain injury. | 2016-03-03 |
20160058727 | Pulmonary Delivery for Levodopa - In one aspect, the invention is related to a method of treating a patient with Parkinson's disease, the method including administering to the respiratory tract of the patient particles that include more than about 90 weight percent (wt %) of levodopa. The particles are delivered to the patient's pulmonary system, preferably to the alveoli or the deep lung. | 2016-03-03 |
20160058728 | CANCER STARVATION THERAPY - The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction. | 2016-03-03 |
20160058729 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 2016-03-03 |
20160058730 | PHARMACEUTICAL COMPOSITIONS OF TERIFLUNOMIDE - The present invention relates to stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof. In particular, the invention relates to the stable pharmaceutical compositions of teriflunomide or a pharmaceutically acceptable salt thereof with colloidal silicon dioxide. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of relapsing forms of multiple sclerosis. | 2016-03-03 |
20160058731 | METHODS OF TREATING LIVER DISEASES - The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2. | 2016-03-03 |
20160058732 | METHOD FOR IMPROVING THE OXYGEN-RELEASING ABILITY OF HEMOGLOBIN TO ORGANS AND PERIPHERAL TISSUES IN HUMAN BODIES AND A MEDICATION THEREOF - A method for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is disclosed by administering a compound of phthalides to a subject in need thereof to improve the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes to the organs and the peripheral tissues in human bodies. The compound of phthalides is characterized by a phthalide functional group, and forms at least one hydrogen bond with αArg141 of hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes, stabilizing the α1/α2 interface of hemoglobin, further stabilizing the oxygenated hemoglobin, hemoglobin variants, recombinant hemoglobin and hemoglobin-based blood substitutes in the low oxygen affinity “T” state and facilitating the oxygen release to the organs and the peripheral tissues. A medication for improving the oxygen-releasing ability of hemoglobin, hemoglobin variants, recombinant hemoglobin, and hemoglobin-based blood substitutes to organs and peripheral tissues in human bodies is also disclosed. | 2016-03-03 |
20160058733 | CDC7 KINASE INHIBITORS AND USES THEREOF - The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): | 2016-03-03 |
20160058734 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE - Compounds represented by the following formula (I); | 2016-03-03 |
20160058735 | METHODS OF TREATING HYPERHIDROSIS - Provided herein are methods of treating hyperhidrosis by administering an effective hyperhidrosis treatment and scoring hyperhidrosis in a subject in need thereof. In some embodiments, the treatment is a glycopyrronium compound and the scoring is an assessment provided herein, or a portion thereof. | 2016-03-03 |
20160058736 | CANNABINOID RECEPTOR ANTAGONISTS/INVERSE AGONISTS USEFUL FOR TREATING METABOLIC DISORDERS, INCLUDING OBESITY AND DIABETES - The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers. | 2016-03-03 |
20160058737 | IMIDAZOLIDINEDIONE DERIVATIVES - The invention provides a compound of formula (Ia), and pharmaceutically acceptable salts thereof. The invention also provides use of the compounds or salts as modulators of Kv3.1 and/or Kv3.2, and in the treatment of diseases or disorders where a modulator of Kv3.1 and/or Kv3.2 is required, such as depression and mood disorders, hearing disorders, schizopherenea, substance abuse disorders, sleep disorders or epilepsy. | 2016-03-03 |
20160058738 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OVARY GRANULOSA CELL TUMORS CONTAINING GLYCOGEN SYNTHASE KINASE-3 BETA INHIBITOR AS ACTIVE INGREDIENT, AND FUNCTIONAL HEALTH FOOD COMPOSITION - A pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing, as an active ingredient, one selected from the group consisting of a compound represented by chemical formula 1, a pharmaceutically acceptable salt of the compound represented by chemical formula 1, a compound represented by chemical formula 2, and a pharmaceutically acceptable salt of the compound represented by chemical formula 2, or a functional health food composition. The composition inhibits glycogen synthase kinase-3 beta (GSK3beta) and thus has an effect of inhibiting a phosphorylation of a serine, which is the 33rd amino acid of the forkhead box L2 (FOXL2) protein. | 2016-03-03 |
20160058739 | USE OF PIDOTIMOD TO TREAT INFLAMMATORY BOWEL DISEASE - The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat inflammatory bowel disease. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally. | 2016-03-03 |
20160058740 | USE OF PIDOTIMOD TO TREAT IRRITABLE BOWEL SYNDROME - The present invention is directed to the use of pidotimod, or a physiologically acceptable salt thereof, to treat irritable bowel syndrome. For the treatment of the present invention, pidotimod, or a physiologically acceptable salt thereof, may be administered either by oral route or rectally. | 2016-03-03 |
20160058741 | Thiadiazolidinone Derivatives - The present invention relates to compounds of the formulae herein, their acceptable salts, solvates, hydrates and polymorphs thereof. The compounds of this invention are useful in treatment of disease, particularly leukemia. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating disease, disorders, or symptoms thereof in a subject. | 2016-03-03 |
20160058742 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS - The present invention relates to HSP90 inhibitors containing fused amino pyridine core that are useful as inhibitors of HSP90 and their use in the treatment of HSP90 related diseases and disorders such as cancer, an autoimmune disease, or a neurodegenerative disease. | 2016-03-03 |
20160058743 | METHODS FOR TREATING SENSORIMOTOR IMPAIRMENTS ASSOCIATED WITH CERTAIN TYPES OF STROKE USING AMINOPYRIDINES - Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke. | 2016-03-03 |
20160058744 | AMELIORATING DRUG-INDUCED ELEVATIONS IN BLOOD PRESSURE BY ADJUNCTIVE USE OF ANTIHYPERTENSIVE DRUGS - Patients which are treated with stimulants (e.g., CNS stimulants, sympathomimetic amine, or anorectic/anorexigenic), such as patients being treated for attention deficit/hyperactivity disorder or obesity, often are at risk in developing high blood pressure. Similarly, patients which are treated with analgesics such as non-steroidal anti-inflammatory drugs (NSAIDs) over an extended period of time risk developing high blood pressure. These and other iatrogenic therapies (therapies which inadvertently cause an increase in, e.g., blood pressure) are addressed by providing the patient with one or more antihypertensive drugs, most preferably calcium channel blockers, during the treatment period. The CNS or NSAIDs can be provided separately or together with the antihypertensive drugs or as part of a combined composition. The adjunctive therapy can prevent or reduces cardiovascular disease and other complications of high blood pressure attendant with these iatrogenic therapies. | 2016-03-03 |
20160058745 | CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS - The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1δ) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease. | 2016-03-03 |
20160058746 | Oral Pharmaceutical Dosage Forms - Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided. | 2016-03-03 |
20160058747 | TRANSPARENT TRANSDERMAL NICOTINE DELIVERY DEVICES - A transparent transdermal delivery device for delivering nicotine which has an Opacity Index of less than 48.6%. | 2016-03-03 |
20160058748 | ANTITUMOR AGENT - Pharmaceuticals which are effective for treatment, prevention, and the like of cancer and have less side effects are disclosed. The antitumor agent of the present invention comprises as an effective ingredient at least one leukotriene inhibitor. Examples of the leukotriene inhibitor includes leukotriene production inhibitors and leukotriene receptor antagonists, and preferred specific examples of the leukotriene inhibitor include montelukast, zafirlukast, pranlukast, and zileuton; pharmaceutically acceptable salts of these compounds; and pharmaceutically acceptable solvates of these compounds and the salts. The leukotriene inhibitor can also be used as a relieving agent for pain accompanying a tumor(s), and as a stromal hyperplasia inhibitor. | 2016-03-03 |
20160058749 | TREATMENTS FOR NEUROPATHY - Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds, which may be formulated in topical lotions. | 2016-03-03 |
20160058750 | METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS - The present disclosure relates generally to methods of treating infections in overweight or obese patients using antibiotics. According to statistics compiled by National Health and Nutrition Examination Survey conducted by the National Center for Health Statistics (NCHS) of the U.S. Centers for Disease Control and Prevention (CDC), in 2009-2010, 35.7% of adults in the United States were found to be obese. Ogden, C.L. NCHS Data Brief 2012, 82, available at http://www.cdc.gov/nchs/data/databiefs/db82.pdf (last visited Mar. 2, 2013). | 2016-03-03 |
20160058751 | COMPOSITION AND METHOD FOR TREATING CANCER - The present disclosure relates to a pharmaceutical composition and a kit to treat cancer. The disclosure provides a combination of compounds for use in the treatment of cancer. The disclosure further provides a process of preparing the composition and a method of treating a cancer associated with a RAS mutation or a RAS mutation along with any other mutation. | 2016-03-03 |
20160058752 | TOPICAL PERIPHERAL NEURO-AFFECTIVE (TPNA) THERAPY FOR NEUROPATHIC CONDITIONS - Formulations and methods of treating peripheral neuropathic conditions in humans is disclosed. | 2016-03-03 |
20160058753 | Nalmefene for Treatment of Patients with Mood Disorder - The present invention relates to nalmefene for use in the treatment of mood disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid mood disorder. The invention further relates to nalmefene for use in the reduction of alcohol consumption in said patients. The invention further relates to nalmefene for use in the treatment of a mood disorder in said patients. | 2016-03-03 |
20160058754 | Nalmefene for Treatment of Patients with Anxiety Disorder - The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disorder. The invention further relates to nalmefene for use in the treatment of an anxiety disorder in said patients. | 2016-03-03 |
20160058755 | Pharmaceutical Composition - Provided herein is a pharmaceutical composition comprising an antagonist, an agonist, a seal coat, and a sequestering polymer, wherein the antagonist, agonist, seal coat and at least one sequestering polymer are all components of a single unit, and wherein the seal coat forms a layer physically separating the antagonist from the agonist from one another. Methods for manufacturing such a pharmaceutical composition are also provided. Methods for treating pain using such compositions is also demonstrated. | 2016-03-03 |
20160058756 | MAST CELL MARKERS AND PREVENTION, DIAGNOSIS, AND THERAPY FOR CHRONIC PELVIC PAIN SYNDROME - The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e g inhibition of MCP-1 and/or MIP-1α) to treat or prevent chronic pelvic pain syndrome. | 2016-03-03 |
20160058757 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE - A heterocyclic compound represented by the general formula (1) or a salt thereof: | 2016-03-03 |
20160058758 | SYK INHIBITORS - The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: | 2016-03-03 |
20160058759 | GLUTAMINASE INHIBITOR THERAPY - Disclosed herein are methods of treating a subject having an altered NRF2/KEAP1 pathway, and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject. | 2016-03-03 |
20160058760 | Protein Kinase C Inhibitors and Uses Thereof - This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. | 2016-03-03 |
20160058761 | Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction - The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes. | 2016-03-03 |
20160058762 | COMBINATIONS OF SEROTONIN RECEPTOR AGONISTS FOR TREATMENT OF MOVEMENT DISORDERS - The present invention relates to the use of 5-HT1 agonists in pharmaceutical compositions, compounds and methods for treatment of movement disorders related to neurological dysfunctions. The invention is particularly relevant for treatment of patients suffering from tardive dyskinesia, Parkinson's disease and associated disorders thereof. Kits of parts comprising the 5-HT1 agonist compounds or pharmaceutical compositions according to the present invention, as well as methods of preparation are also provided by the present invention. | 2016-03-03 |
20160058763 | NOVEL HETEROCYCLIC CARBOXAMIDES AS MODULATORS OF KINASE ACTIVITY - The invention provides novel heterocyclic carboxamide compounds according to Formula (I) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer. | 2016-03-03 |
20160058764 | METHODS FOR TREATING HAIR LOSS DISORDERS - The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor. | 2016-03-03 |
20160058765 | METHODS FOR TREATING HAIR LOSS DISORDERS - The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor. | 2016-03-03 |
20160058766 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH DEPRESSION - The present invention provides assays, methods and compositions for selecting a treatment regimen for a patient having depression or at risk for depression and/or treating at least one symptom of depression in the subject, based on the recognition that specific combinations of single nucleotide polymorphisms (SNPs) are associated with a therapeutic response to a folate-comprising compound. Provided herein are also methods for improving the effectiveness of an antidepressant drug administered to a subject with depression or at risk for depression by administering an adjunctive therapy of a folate-comprising compound to the subject if the subject carries a specific combination of SNPs that are predictive of a therapeutic response. Furthermore, provided herein are compositions of the folate-comprising compound. | 2016-03-03 |
20160058767 | COMPOSITIONS AND METHODS OF INHIBITING IL-17 EXPRESSION OF NEUTROPHILS - A method of inhibiting IL-17 expression in neutrophils of a subject in need thereof includes administering to neutrophils of the subject a therapeutically effective amount of agent that inhibits STAT3 mediated IL-17 expression in the neutrophils of the subject. | 2016-03-03 |
20160058768 | SUBSTITUTED AMIDE COMPOUNDS - The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. | 2016-03-03 |
20160058769 | TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG - The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug. | 2016-03-03 |
20160058770 | USE OF SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINES FOR TREATING LYMPHOMAS - —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd line, relapsed, refractory, indolent or aggressive non-Hodgkin's lymphoma (NHL), in particular follicular lymphoma (FL), chronic lymphocytic leukaemia (CLL), marginal zone lymphoma (MZL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), transformed lymphoma (TL), or peripheral T-cell lymphoma (PTCL); —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of the expression of PI3K isoforms, BTK and IKK, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2, for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and —a method of determining the level of a component of one or more of the expression of PI3K isoforms, BTK and IKK, BCR activation, BCR downstream activation of NFKB pathway, c-Myc, EZH2. | 2016-03-03 |
20160058771 | ALPHA-2 ADRENOCEPTOR AND SIGMA RECEPTOR LIGAND COMBINATIONS - The invention refers to a combination comprising a Sigma ligand of general formula (I) and alpha-2-adrenergic agonist compound, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and/or treatment of pain. | 2016-03-03 |
20160058772 | BISMUTH-THIOLS AS ANTISEPTICS FOR BIOMEDICAL USES, INCLUDING TREATMENT OF BACTERIAL BIOFILMS AND OTHER USES - Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections. | 2016-03-03 |
20160058773 | FULVESTRANT FORMULATIONS - Fulvestrant formulations suitable for intramuscular injection at concentration in excess of 40 mg/ml in the absence of castor oil and castor oil derivatives are disclosed. | 2016-03-03 |
20160058774 | SEX STEROID PRECURSORS ALONE OR IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE PREVENTION AND TREATMENT OF DYSPAREUNIA IN POSTMENOPAUSAL WOMEN - Novel methods for treating or reducing the likelihood of acquiring vaginal dysfunctions, more particularly vaginal dryness and dyspareunia, leading to sexual dysfunction and low sexual desire and performance, in susceptible warm-blooded animals including humans involving administration of a sex steroid precursor. Further administration of estrogen or selective estrogen receptor modulator, particularly those selected from the group consisting of Raloxifene, Arzoxifene, Tamoxifen, Droloxifene, Toremifene, Iodoxifene, GW 5638, TSE-424, ERA-923, and lasofoxifene, and more particularly compounds having the general structure: | 2016-03-03 |
20160058775 | COMPOSITION AND FORMULATION OF ANTIMICROBIAL AGENTS, PROCESSES THEREOF AND METHODS FOR TREATING MICROBIAL INFECTIONS - The present disclosure provides compositions comprising antimicrobial agent and excipient, wherein the composition is devoid of fatty acids or their esters having more than 10 carbons. The present disclosure also provides compositions comprising antimicrobial agent and excipient, wherein the composition has at least one fatty acid/ester with carbon chain smaller than C11, and wherein the composition is devoid of fatty acids or their esters having more than 10 carbons. In an embodiment of the present disclosure, the compositions are a nanocomposite wherein particle size of at least one component is in nanoscale range. Further, the present disclosure also relates to formulating said compositions in a manner wherein, particle size or globule size of the formulation is in nanoscale range. The present disclosure also provides process for obtaining said compositions or formulations along with methods for treating microbial infections by using the compositions or the formulations of the present disclosure. | 2016-03-03 |
20160058776 | ACTIVE AGENTS AND THEIR OLIGOMERS AND POLYMERS - Conjugates comprising at least two active agents linked by a diglycolic acid or polyglycol diacid linker are disclosed. The invention also concerns oligomers and polymers of these conjugates and their use in therapeutic and industrial applications for localized, immediate or fast release delivery of an active agent, such as an anti-microbial, anti-infective, or antiseptic agent. | 2016-03-03 |
20160058777 | IDENTIFICATION AND TREATMENT OF CANCER SUBSETS - Methods of predicting whether or not a tumor will be responsive to IP6 treatment, methods of treating patients with cancer using IP6, methods of predicting the progression of a disease, and kits that facilitate these methods are disclosed. | 2016-03-03 |
20160058778 | METHOD OF PRODUCING THERAPEUTIC AGENT - The present invention relates to a therapeutic agent, wherein the therapeutic agent is D-Boramine. The therapeutic agent is prepared by mixing L-carnitine tartrate, pyridoxal 5′ phosphate and fumaric acid. D-Boramine, when administered orally or parenterally in therapeutic quantities, is effective for use in the prevention of cancer that arises from mutations to the BRCA1 and BRCA2 genes, i.e., breast and ovarian and the treatment of several types of human diseases including, but not limited to, Antiphospholipid Syndrome, Disseminate Intravascular Coagulation (DIC), infections arising from viruses (including strains of Human Papillomavirus, Herpes Simplex Virus and Simian Virus), tuberculosis (including XDR Tuberculosis) and mycoplasma, Hepatitis A, B and C, MTHFR genetic mutations. | 2016-03-03 |
20160058779 | METHODS FOR TREATING VIRAL INFECTIONS USING HYDROGEN SULFIDE DONORS - Certain embodiments are directed to methods of treating respiratory infection by administering an H | 2016-03-03 |
20160058780 | COMPOSITION FOR LIPOLYSIS, CONTAINING PHOSPHATIDYLCHOLINE, AND PREPARATION METHOD THEREFOR - A composition for inducing lipolysis includes phosphatidylcholine and a preparation method therefor. More particularly, the composition for inducing lipolysis may include 2-12% (w/v) of phosphatidylcholine, 5-12% (w/v) of an oily solvent, and a balance of water; and a preparation method thereof. The composition may include phosphatidylcholine, an oily solvent, and water to induce lipolysis without causing such adverse side effects as edema, erythema, tissue necrosis, and inflammation. | 2016-03-03 |
20160058781 | Compositions And Methods For Borocarbohydrate Complexes - Borocarbohydrate complex containing compositions are presented that have an improved di-complex to boric acid ratio. In some embodiments, compositions are characterized by a di-complex to boric acid ratio of at least 5:1 and more typically at least 10:1 in liquid form, and at least 20:1 in dried form. In other embodiments, compositions are characterized by a minimum content of 80 wt % di-complex and a boric acid content of less than 15 wt %, and more typically less than 5 wt %. Contemplated compositions are thought to have improved biological activity and reduced content of undesired components. | 2016-03-03 |
20160058782 | MAILLARD REACTION INHIBITOR - A Maillard reaction inhibitor which effectively inhibits the progress of a Maillard reaction in a living body, can be safely applied without adverse side effects, can be manufactured without any complicated process, a skin anti-aging agent, an anti-diabetic complication agent and foods and beverages using the same. The Maillard reaction inhibitor contains 50 to 90% by mass of polyphenol as an active ingredient. The Maillard reaction inhibitor has a potent Maillard reaction inhibitory activity in a living body and allows for the prevention and improvement of the various dysfunction of protein in a living body. Due to this activity, the Maillard reaction inhibitor suppresses aging and can prevent and/or treat diabetic complications. Furthermore, when the above-described tannin is mixed in foods and beverages containing collagen, it is possible to suppress the Maillard reaction in the foods and beverages to suppress the deterioration of the foods and beverages. | 2016-03-03 |
20160058783 | NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES - The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: | 2016-03-03 |
20160058784 | ANTI-TUMOR COMPOSITIONS AND METHODS - Disclosed herein are oligonucleotide sequences that generate innate immunity in cells within tumors upon its delivery into tumors. In certain embodiments, these oligonucleotides are specifically delivered into tumors through nanoparticles displaying targeting peptides that confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells. | 2016-03-03 |
20160058785 | GALACTOSE-PRONGED POLYSACCHARIDES IN A FORMULATION FOR ANTIFIBROTIC THERAPIES - Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-β1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis. | 2016-03-03 |
20160058786 | FORMULATIONS CONTAINING CLOPIDOGREL AND SULFOALKYL ETHER CYCLODEXTRIN AND METHODS OF USE - The present invention provides compositions containing clopidogrel, present as a free base or a pharmaceutically acceptable salt thereof, and sulfoalkyl ether cyclodextrin (SAE-CD). The compositions can be liquid, suspension or solid compositions. They can be adapted for oral, peroral or parenteral administration. The SAE-CD serves to aid in dissolution and stabilization of the clopidogrel in aqueous media. The stability of clopidogrel against hydrolytic degradation, thermal degradation, and photolytic degradation are improved. SAE-CD provides improved results over other cyclodextrin derivatives. The SAE-CD-containing composition of clopidogrel can be provided in liquid form, solid form or as a reconstitutable powder. Both ready-to-use and concentrated liquid compositions can be prepared. The liquid composition is optionally available as a clear solution. The compositions herein can be administered perorally or parenterally and provide substantial pharmacokinetic, pharmacodynamic and/or therapeutic advantages over a tablet composition administered perorally and excluding SAE-CD. | 2016-03-03 |
20160058787 | Therapy and Cure of Ebola - A therapeutic model for the expedient treatment of deadly pathogens involved in pandemics and bioterrorism related events. The immune pathogenesis of deadly pathogens is redefined in the light of Recent advances in the Fundamentals of Immunology by developing three dimensional understandings of deadly pathogens and its interactions with host and its immune system. The immune pathogenesis of deadly pathogens can be treated expediently and globally with NSPS to mitigate the threat of bioterrorism and pandemics. According to a method for treating deadly pathogens having an immune regulatory molecule, the first step is providing a nano-engineered formulation of sodium polystyrene sulfonate (NSPS) having particle size less than 100 nm. A pharmaceutically effective dose of the NSPS is administered to a patient infected with the pathogen. The immune regulatory molecule is targeted with the NSPS for inhibiting serine protease activation. The therapeutic model is further extended for quarantine purposes to facilitate decontamination measures for patients, hospitals and laboratories. | 2016-03-03 |
20160058788 | MULTIPLE PPI DOSAGE FORM - Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml. | 2016-03-03 |
20160058789 | CLOSTRIDIUM DIFFICILE SPORICIDAL COMPOSITIONS - Disclosed are sporicidal compositions, and methods of use thereof. The sporicidal compositions contain water, an organic solvent, and a spore-germinating agent containing an iodide source, a citrate source or both. The compositions have sporicidal activity against, e.g., | 2016-03-03 |
20160058790 | ANTIVIRAL GEL COMBINATION - The present invention relates to an antiviral gel combination. The said gel is composed of a boron compound, and the poloxamer and chlorhexidine compounds; and the gel obtained with the present invention demonstrates high activity on Herpes Simplex Type 1 Virus (HSV). | 2016-03-03 |
20160058791 | USE OF TRANSPLATIN TO PREVENT HEARING LOSS - Methods and compositions for treating and preventing toxic side effects of platinum-based chemotherapy agents are disclosed, in which transplatin is administered to a subject. Transplatin is shown to have protective effects against cisplatin-induced ototoxicity, nephotoxicity and neurotoxicity. Anti-inflammatory activity of transplatin is demonstrated and methods and compositions for treating and preventing inflammatory pain are described. | 2016-03-03 |
20160058792 | METHODS AND COMPOSITIONS OF TREATING AUTOIMMUNE DISEASES - Embodiments of various aspects described herein are directed to methods and compositions for producing a tolerogenic or immunosuppressive dendritic cell. In particular, an immunosuppressive dendritic cell can be produced by contacting a dendritic cell with an agent that stimulates the IL 27/ectonucleotidase CD39 axis signaling. In some embodiments, the methods and/or compositions described herein can be used for treating an autoimmune disease or disorder, e.g., but not limited to multiple sclerosis (MS) and type 1 diabetes. | 2016-03-03 |
20160058793 | Tumor Targeted Sickle Erythroid Precursors, Progenitors and Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Microparticles and Liposomes for Treatment of Cancer - The present invention contemplates a method of treating cancer comprising CD47 deficient sickle cell erythroid precursors/progenitors or hematopoietic stem cells transduced with viral altered genomic DNA from normal or tumor bearing hosts and used to polarize macrophages and/or activate a cytotoxic T cell tumoricidal response. | 2016-03-03 |
20160058794 | LYMPH NODE AS A SITE FOR TRANSPLANTATION, ORGANOGENESIS AND FUNCTION FOR MULTIPLE TISSUES AND ORGANS - The present invention relates to methods and compositions for transplanting non-lymphoid tissues into lymphoid organs. It may be used to cultivate organ tissues including for the purpose of supplementing or reconstituting organ function. Tissues that may be propagated in this manner include but are not limited to lung, kidney, thyroid, intestine, and brain. | 2016-03-03 |
20160058795 | Adult Stem Cells/Progenitor Cells and Stem Cell Proteins for Treatment of Eye Injuries and Diseases - The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal. | 2016-03-03 |
20160058796 | RETINA EXTRACELLULAR MATRIX BASED BIOMATERIAL - The present technology relates to compositions and methods useful for preventing and treating degenerative eye diseases or disorders. The compositions and methods include ocular biomaterials. In some embodiments, the ocular biomaterial compositions include retinal biomaterial, interphotoreceptor matrix biomaterial or a combination thereof. In some embodiments, the ocular biomaterial compositions are formed into films, gels, scaffolds and matrices for cell delivery. | 2016-03-03 |
20160058797 | PHARMACEUTICAL COMPOSITION AND METHOD FOR REGENERATING MYOFIBERS IN THE TREATMENT OF MUSCLE INJURIES - A pharmaceutical composition and method for regenerating cardiomyocytes in treating or repairing heart muscle damages or injuries caused by an ischemic disease. The pharmaceutical composition contains an active ingredient compound with a backbone structure of Formula (I). The active ingredient compound is capable of (a) increasing viability of myogenic precursor cells to enable said precursor cells to survive through an absolute ischemic period; (b) reconstituting a damaged blood supply network in said heart region where said injured muscle is located; and (c) enhancing cardiomyogenic differentiation efficiency of said precursor cells down cardiac linage, said steps being performed simultaneously or in any particular order. | 2016-03-03 |
20160058798 | METHOD OF TREATING PANCREATIC AND LIVER CONDITIONS BY ENDOSCOPIC-MEDIATED (OR LAPAROSCOPIC-MEDIATED) TRANSPLANTATION OF STEM CELLS INTO/ONTO BILE DUCT WALLS OF PARTICULAR REGIONS OF THE BILIARY TREE - A method of repairing diseased or dysfunctional pancreas or liver is provided. The method involves preparation of a suspension of stem cells and/or progenitor cells such as biliary tree stem cells, hepatic stem cells, pancreatic stem cells or their descendants, committed progenitor cells, from healthy tissue of the patient or of the biliary tree of a non-autologous donor and engrafting the cells into the wall of bile ducts near to the organ to be treated. The graft consists of stem cells or progenitors that are admixed with biomaterials and, optionally, with cytokines and/or native epithelial-mesenchymal cells appropriate for the maturational lineage stage of the cells to be engrafted. The cells are specifically introduced to the hepato-pancreatic common duct of the subject for treatment of pancreatic conditions or to the bile duct wall near to the liver for treatment of liver conditions and allowed to migrate to the pancreas or to the liver and expand and then rebuild part or the entirety of the diseased or dysfunctional organ. | 2016-03-03 |
20160058799 | ADHERENT CELLS FROM PLACENTA AND USE OF SAME IN DISEASE TREATMENT - Methods for treating conditions by administration of placenta derived adherent stromal cells to a subject in thereof are provided. Such conditions include skeletal muscle defects, neuropathic pain, and myocardial infarction. Also provided are methods wherein the adherent stromal cells administered are cultured under 2 dimensional or 3 dimensional growth conditions. Also provided are methods in which the cells administered are at least 70% adherent cells from a maternal or fetal portion of the placenta. | 2016-03-03 |
20160058800 | PLURIPOTENT STEM CELL FOR TREATMENT OF CHRONIC KIDNEY DISEASE - An object of the present invention is to provide a novel medical application to regenerative medicine that uses pluripotent stem cells (Muse cells). The present invention provides a cell preparation for treating chronic kidney disease that contains SSEA-3-positive pluripotent stem cells isolated from mesenchymal tissue in the body or cultured mesenchymal cells. The cell preparation of the present invention is based on a renal tissue regeneration mechanism by which Muse cells are made to selectively accumulate at a site of kidney disease and differentiate into cells that compose the kidney by administering Muse cells intravenously to a subject having the aforementioned disease. | 2016-03-03 |
20160058801 | COMPOSITION AND METHOD TO IMPROVE BLOOD LIPID PROFILES AND OPTIONALLY REDUCE LOW DENSITY LIPOPROTEIN (LDL) PER-OXIDATION IN HUMANS - A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from | 2016-03-03 |
20160058802 | DERMAL COMPOSITIONS CONTAINING GORGONIAN EXTRACT - A skincare composition comprising Gorgonian extract as an anti-inflammatory component thereof, said skincare composition being selected from among compositions (I) and (II): (I) an aqueous composition comprising from 35 to 65 wt. % water, from 25 to 45 wt. % surfactant, from 0.01 to 0.2 wt. % retinol and from 0.005 to 0.5 wt. % Gorgonian extract, wherein all weight percentages are based on total weight of the aqueous face wash composition, and all weight percentages of all ingredients in the aqueous face wash composition total to 100 wt. %; and (II) a gel composition comprising from 60 to 90 wt. % water, from 1 to 12 wt. % benzoyl peroxide, and from 0.05 to 1.25 wt. % Gorgonian extract, wherein all weight percentages are based on total weight of the gel composition, and all weight percentages of all ingredients in the gel composition total to 100 wt. %. | 2016-03-03 |
20160058803 | ADJUNCTS FOR GASTROINTESTINAL DEVICES - An adjunct for a gastrointestinal device and a system including said adjunct are described herein and include a substrate configured to attach to a gastrointestinal device, the substrate including a first surface and a second surface, and at least one microbe-promoting agent associated with at least one of the first surface and the second surface of the substrate, the at least one microbe-promoting agent configured to promote at least one of attraction, colonization, and growth of at least one type of commensal microbe. | 2016-03-03 |
20160058804 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method for manufacturing a microbiota restoration therapy composition may include collecting a human fecal sample and adding a diluent to the human fecal sample to form a diluted sample. The diluent may include a cryoprotectant. The method may also include mixing the diluted sample with a mixing apparatus and filtering the diluted sample. Filtering may form a filtrate. The method may also include transferring the filtrate to a sample bag and sealing the sample bag. | 2016-03-03 |
20160058805 | PROCESS FOR ENHANCING THE VIABLE COUNTS OF LACTIC ACID BACTERIA AND USEFUL COMPOSITIONS THEREOF - The present invention disclosed herein describes (i) the growth promotional activity of natural plant based fibres on | 2016-03-03 |
20160058806 | METHOD FOR STIMULATING INTESTINAL BARRIER INTEGRITY AFTER NON-NATURAL BIRTH - The present invention relates to methods for feeding and stimulating the health of infants delivered via caesarean section comprising administering long chain polyunsaturated fatty acids and/or nucleotides. | 2016-03-03 |
20160058807 | COMPOSITION CONTAINING BACTERIUM BELONGING TO GENUS LACTOBACILLUS - A composition containing a | 2016-03-03 |
20160058808 | MICROBE-BASED MODULATION OF SEROTONIN BIOSYNTHESIS - Methods and compositions that can be used to modulate serotonin level in a subject are disclosed herein. In some embodiments, the methods include adjusting the composition of gut microbiota in the subject. Also disclosed are methods of adjusting the level of one or more serotonin-related metabolites to modulate serotonin biosynthesis in a subject, and methods for treating serotonin-related diseases, for example disorders caused by serotonin deficiency. | 2016-03-03 |
20160058809 | Additional Artemisinin and Berberine Compositions and Methods of Making - An Alternative ACT composition consisting of natural botanical active ingredients, all of which are GRAS (generally regarded as safe by the FDA). The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives, berberine, capsaicin, and papaya extract. The four active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for the treatment and prevention of chikungunya. | 2016-03-03 |
20160058810 | COMPOSITION CONTAINING ANGELICA EXTRACT FOR PROMOTING PROLIFERATION OF STEM CELLS DERIVED FROM BONE MARROW - The present invention relates to a composition for promoting proliferation of bone marrow derived stem cells using an angelicae gigantis radix extract, and more particularly, to a composition which administers a granulocyte colony-stimulating factor into an object, and administers the angelicae gigantis radix extract to the object to promote the proliferation of the bone marrow derived stem cells. The composition of the present invention solves side effects such as splenomegaly which were caused by a method of administering only the G-CSF for proliferation and differentiation of the stem cells, thereby significantly mitigating the side effects through co-administration of the angelicae gigantis radix extract, and further promoting the proliferation and the differentiation of the stem cells. | 2016-03-03 |
20160058811 | COMPOSITION FOR IMPROVING HEALTH AND QUALITY OF LIFE OF WOMEN CONTAINING GINSENG BERRY EXTRACT - The present invention relates to a composition which improves the quality of life of women by containing a ginseng berry extract as an active ingredient, and more specifically, to a composition which promotes the general psychological and physical health of women and improving the sexual function and sex life satisfaction women. | 2016-03-03 |
20160058812 | COMPOSITIONS FOR THE TREATMENT OF PERIPHERAL ULCERS OF VARIOUS ORIGINS - The present invention relates to combinations of an agent that stimulates cell proliferation and an anti-inflammatory/analgesic, which are useful in the treatment of peripheral ulcers of various origins, such as radiation dermatitis, diabetic ulcers, ulcers caused by venous stasis of the limbs, bedsores, and the associated skin infections, proctitis, vulvovaginitis and haemorrhoids with vascular lesions. These combinations can be presented as formulations for topical use. | 2016-03-03 |
20160058813 | Pea (Pisum sativum L.) Seed Coats and Seed Coat Fractions - The present disclosure embraces methodology and compositions for preparing pea seed coat fractions conferring improved health and/or other beneficial effects, and such fractions may be used in a human and/or animal diet. | 2016-03-03 |
20160058814 | PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Ehanolic plant extracts of aerial parts of at least a first plant, a second plant and optionally a third plants are described with related compositions, methods and systems, in which the first plant belongs to plant genus | 2016-03-03 |
20160058815 | SKIN SALVE FOR TREATING INTERTRIGO - The subject patent discloses a method for treating intertrigo on the underside of a female breasts which comprises (1) applying a skin salve to the underside of the female breasts, wherein the female breasts are dry, and wherein the skin salve is comprised of (i) petrolatum, (ii) from 11 weight percent to 60 weight percent beeswax, and (iii) from 0.25 weight percent to 10 weight percent peppermint oil, wherein the skin salve has a viscosity at 25° C. which is within the range of 11 Pa·s to 15 Pa·s at a shear rate of 35 l/s, and (2) allowing the skin salve to remain in contact with female breasts for a period of at least 4 hours. | 2016-03-03 |
20160058816 | METHODS FOR TREATING SCARS AND AGING SKIN - Beneficial topical compositions for treating scar or aging skin are provided. In one embodiment, the compositions include | 2016-03-03 |
20160058817 | Treatment of precancerous lesions with Sanguinaria Canadensis Extract/Compounded Extract - The present invention relates to a novel extract of the plant | 2016-03-03 |
20160058818 | COMPOSITIONS AND METHODS FOR RELIEF FROM COLD SORES - The invention provides compositions and methods that relieve pain and reduce the duration of cold sore episodes to a period of at most 3 to 5 days. Specifically, the invention provides a combination of extracts of bitter orange ( | 2016-03-03 |
20160058819 | COMPOSITIONS OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREFORE - A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement. | 2016-03-03 |
20160058820 | METHODS AND COMPOUNDS FOR INTENSIVE SKIN REPAIR AND HEALING INCLUDING ACTIVE ORGANIC AND SYNTHETIC COMPOUNDS - A skin treatment compound includes Lidocaine and | 2016-03-03 |
20160058821 | PLANT BASED FORMULATION FOR THE PREVENTION AND MANAGEMENT OF OBESITY AND ASSOCIATED COMPLICATIONS - The invention relates to a plant based formulation for the prevention and management of obesity and associated complications comprising of an effective amount of hydro-alcoholic extract of | 2016-03-03 |
20160058822 | RADIOPAQUE INJECTABLE NUCLEUS HYDROGEL COMPOSITIONS - A composition suitable for use as replacement material for all or part of a disc nucleus during percutaneous injection, the composition comprising:
| 2016-03-03 |
20160058823 | COMPOSITION AND USE OF A DIETARY SUPPLEMENT - Composition of a dietary supplement, characterised in that it comprises a mixture of at least a-casein tryptic hydrolysate, Siberian or Asian Ginseng root powder, and lyophilised melon extract. | 2016-03-03 |